CFC supports greater transparency for prescription drug pricing (SB 17)

SB 17 (Hernandez) will promote transparency by requiring pharmaceutical companies to give prior notice to purchasers before raising prices, and to provide the state with an explanation for a drug’s price increase.

Updates

4/19/17 SB 17 cleared the Senate Health committee on a 7-2 vote.

Tags: , ,